<DOC>
	<DOCNO>NCT02204345</DOCNO>
	<brief_summary>A multi-center Phase Ib/II study combination RO5479599 carboplatin paclitaxel every 3 week ( q3w ) regimen evaluate safety tolerability .</brief_summary>
	<brief_title>A Study Evaluating RO5479599 Combination With Carboplatin Paclitaxel Participants With Advanced Metastatic Non-Small-Cell Lung Cancer ( NSCLC ) Squamous Histology</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Participants Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 01 Locally advance metastatic ( stage IIIB IV ) squamous NSCLC No prior systemic chemotherapy , target therapy metastatic NSCLC Evidence least one radiologically measurable lesion per RECIST version 1.1 Adequate hematological , liver renal function Participants must agree either remain completely abstinent use effective contraceptive method screen 6 month last dose study treatment Histologically confirm squamous NSCLC participant eligible enrollment must provide archival tumor biopsy tissue unavailable must willing undergo fresh pretreatment primary tumor metastatic biopsy Participants Gilbert 's Syndrome eligible study Concurrent therapy investigational drug History clinical evidence central nervous system ( CNS ) primary tumor metastases Evidence significant , uncontrolled concomitant disease , could affect compliance protocol interpretation result , include uncontrolled diabetes mellitus and/or significant cardiovascular disease uncontrolled infection Any disease , metabolic dysfunction , physical examination find clinical laboratory finding , give reasonable suspicion disease condition would contraindicate use investigational drug Major surgery significant traumatic injury le ( &lt; ) 28 day prior first study treatment infusion ( exclude biopsy ) anticipation need major surgery study treatment Pregnant breastfeed woman History malignancy could affect compliance protocol interpretation result . Participants malignancy diagnose 5 year prior study day one , adequately treat carcinoma situ cervix basal squamous cell skin cancer generally eligible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>